Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjug
2026-04-15
电车资讯
<p>Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.1 The Phase 1 clinical trial for SBE303 is an open‑label, multi-center, first‑in‑human trial to evaluate the safety, tolerability and efficacy of SBE303 in participants with advanced refractory solid tumors. More information on this study is available at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07524348&esheet=54502327&newsitemid=20260414313544&lan=en-US&anchor=clinicaltrials.gov&index=1&md5=6a3334139eda06e75b7185ec6a08024e" rel="nofollow" target="_blank">clinicaltrials.gov</a> (NCT07524348).</p>
<p>About Samsung Bioepis Co., Ltd.</p>
<p>Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, endocrinology. For more information, please visit <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.samsungbioepis.com&esheet=54502327&newsitemid=20260414313544&lan=en-US&anchor=www.samsungbioepis.com&index=2&md5=9aa914a4dde086776acc24d58438bbe6" rel="nofollow" target="_blank">www.samsungbioepis.com</a> and follow us on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsamsungbioepis%2F&esheet=54502327&newsitemid=20260414313544&lan=en-US&anchor=LinkedIn&index=3&md5=44833481a220e312b44d30f7d973492c" rel="nofollow" target="_blank">LinkedIn</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2FSamsungBioepis%2F&esheet=54502327&newsitemid=20260414313544&lan=en-US&anchor=X&index=4&md5=b614b0becd1de097f4ddf82ff52aa1e3" rel="nofollow" target="_blank">X</a>.</p>
<table cellspacing="0" id="ui-kit-table-container-1">
<tbody>
<tr>
<td> </td>
<td> </td>
</tr>
<tr>
<td colspan="2">
<p>1 Li K, Zhou Y, Zang M, Jin X, Li X. Therapeutic prospects of nectin-4 in cancer: applications and value. Front Oncol. 2024 Mar 28;14:1354543. doi: 10.3389/fonc.2024.1354543. PMID: 38606099; PMCID: PMC11007101.</p>
</td>
</tr>
</tbody>
</table>
<p> </p>